T1	Participants 330 449	Of 813 patients with previously untreated metastatic colorectal cancer, we randomly assigned 402 to receive irinotecan,
T2	Participants 563 594	411 to receive IFL plus placebo
T3	Participants 1071 1086	group given IFL
T4	Participants 838 853	group given IFL
T5	Participants 908 937	group given IFL plus placebo,
T6	Participants 838 871	group given IFL plus bevacizumab,
T7	Participants 1085 1104	L plus bevacizumab,
T8	Participants 1140 1168	group given IFL plus placebo
T9	Participants 1434 1462	group given IFL plus placebo
T10	Participants 1365 1397	group given IFL plus bevacizumab
